Skip to main content
SpringerLink
Log in

CRISPR-Mediated Approaches to Regulate YAP/TAZ Levels

  • Protocol
  • First Online:
The Hippo Pathway

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1893))

  • 3447 Accesses

Abstract

The advent of CRISPR has revolutionized genomic engineering, and harnessing its power to regulate levels of the transcriptional co-activators YAP and TAZ represents an exciting new opportunity in the field of Hippo signaling. Initially repurposed from the microbial immune system to perform highly specific gene knockouts, CRISPR technology has now been expanded to modulate the transcriptional activity of any gene of interest in mammalian systems. Here, we describe strategies to employ CRISPR to genetically knock out the genes encoding for YAP (YAP1) or TAZ (WWTR1) in mammalian cell lines, as well as briefly outline an approach for utilizing CRISPR to transcriptionally modulate YAP/TAZ levels.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Huang J, Wu S, Barrera J, Matthews K, Pan D (2005) The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell 122(3):421–434. https://doi.org/10.1016/j.cell.2005.06.007

    Article  CAS  PubMed  Google Scholar 

  2. Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, Zhao S, Xiong Y, Guan KL (2008) TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol 28(7):2426–2436. https://doi.org/10.1128/MCB.01874-07

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Meng Z, Moroishi T, Guan K-L (2016) Mechanisms of Hippo pathway regulation. Genes Dev 30(1):1–17. https://doi.org/10.1101/gad.274027.115

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Yu F-X, Guan K-L (2013) The Hippo pathway: regulators and regulations. Genes Dev 27(4):355–371. https://doi.org/10.1101/gad.210773.112

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ganem Neil J, Cornils H, Chiu S-Y, O’Rourke Kevin P, Arnaud J, Yimlamai D, Théry M, Camargo Fernando D, Pellman D (2014) Cytokinesis failure triggers hippo tumor suppressor pathway activation. Cell 158(4):833–848. https://doi.org/10.1016/j.cell.2014.06.029

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Aragona M, Panciera T, Manfrin A, Giulitti S, Michielin F, Elvassore N, Dupont S, Piccolo S (2013) A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell 154(5):1047–1059. https://doi.org/10.1016/j.cell.2013.07.042

    Article  CAS  PubMed  Google Scholar 

  7. Halder G, Dupont S, Piccolo S (2012) Transduction of mechanical and cytoskeletal cues by YAP and TAZ. Nat Rev Mol Cell Biol 13:591. https://doi.org/10.1038/nrm3416

    Article  CAS  PubMed  Google Scholar 

  8. Paramasivam M, Sarkeshik A, Yates JR, Fernandes MJG, McCollum D (2011) Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor. Mol Biol Cell 22(19):3725–3733. https://doi.org/10.1091/mbc.E11-04-0300

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Wada K-I, Itoga K, Okano T, Yonemura S, Sasaki H (2011) Hippo pathway regulation by cell morphology and stress fibers. Development 138(18):3907–3914. https://doi.org/10.1242/dev.070987

    Article  CAS  PubMed  Google Scholar 

  10. Zhao B, Li L, Wang L, Wang C-Y, Yu J, Guan K-L (2012) Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev 26(1):54–68. https://doi.org/10.1101/gad.173435.111

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, Zheng P, Ye K, Chinnaiyan A, Halder G, Lai Z-C, Guan K-L (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21(21):2747–2761. https://doi.org/10.1101/gad.1602907

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Nishioka N, Inoue K, Adachi K, Kiyonari H, Ota M, Ralston A, Yabuta N, Hirahara S, Stephenson RO, Ogonuki N, Makita R, Kurihara H, Morin-Kensicki EM, Nojima H, Rossant J, Nakao K, Niwa H, Sasaki H (2009) The Hippo signaling pathway components Lats and Yap pattern Tead4 activity to distinguish mouse trophectoderm from inner cell mass. Dev Cell 16(3):398–410. https://doi.org/10.1016/j.devcel.2009.02.003

    Article  CAS  PubMed  Google Scholar 

  13. Moroishi T, Hansen CG, Guan KL (2015) The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer 15(2):73–79. https://doi.org/10.1038/nrc3876

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Johnson R, Halder G (2014) The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov 13(1):63–79. https://doi.org/10.1038/nrd4161

    Article  CAS  PubMed  Google Scholar 

  15. Harvey KF, Zhang X, Thomas DM (2013) The Hippo pathway and human cancer. Nat Rev Cancer 13(4):246–257. https://doi.org/10.1038/nrc3458

    Article  CAS  PubMed  Google Scholar 

  16. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan S-T, Luk JM, Wigler M, Hannon GJ, Mu D, Lucito R, Powers S, Lowe SW (2006) Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125(7):1253–1267. https://doi.org/10.1016/j.cell.2006.05.030

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, Montgomery EA, Anders RA (2008) Expression of Yes-associated protein in common solid tumors. Hum Pathol 39(11):1582–1589. https://doi.org/10.1016/j.humpath.2008.04.012

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Bhat KP, Salazar KL, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F, James JD, Gumin J, Diefes KL, Kim SH, Turski A, Azodi Y, Yang Y, Doucette T, Colman H, Sulman EP, Lang FF, Rao G, Copray S, Vaillant BD, Aldape KD (2011) The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev 25(24):2594–2609. https://doi.org/10.1101/gad.176800.111

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti A, Daidone MG, Dupont S, Basso G, Bicciato S, Piccolo S (2011) The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147(4):759–772. https://doi.org/10.1016/j.cell.2011.09.048

    Article  CAS  PubMed  Google Scholar 

  20. Horvath P, Barrangou R (2010) CRISPR/Cas, the immune system of bacteria and archaea. Science 327(5962):167–170. https://doi.org/10.1126/science.1179555

    Article  CAS  PubMed  Google Scholar 

  21. Makarova KS, Haft DH, Barrangou R, Brouns SJ, Charpentier E, Horvath P, Moineau S, Mojica FJ, Wolf YI, Yakunin AF, van der Oost J, Koonin EV (2011) Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol 9(6):467–477. https://doi.org/10.1038/nrmicro2577

    Article  CAS  PubMed  Google Scholar 

  22. Bhaya D, Davison M, Barrangou R (2011) CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. Annu Rev Genet 45:273–297. https://doi.org/10.1146/annurev-genet-110410-132430

    Article  CAS  PubMed  Google Scholar 

  23. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339(6121):819–823. https://doi.org/10.1126/science.1231143

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM (2013) RNA-guided human genome engineering via Cas9. Science 339(6121):823–826. https://doi.org/10.1126/science.1232033

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J (2013) RNA-programmed genome editing in human cells. elife 2:e00471. https://doi.org/10.7554/eLife.00471

    Article  PubMed  PubMed Central  Google Scholar 

  26. Cho SW, Kim S, Kim JM, Kim JS (2013) Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 31(3):230–232. https://doi.org/10.1038/nbt.2507

    Article  CAS  PubMed  Google Scholar 

  27. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F (2013) Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8:2281. https://doi.org/10.1038/nprot.2013.143

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Hsu PD, Lander ES, Zhang F (2014) Development and applications of CRISPR-Cas9 for genome engineering. Cell 157(6):1262–1278. https://doi.org/10.1016/j.cell.2014.05.010

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA (2013) Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152(5):1173–1183. https://doi.org/10.1016/j.cell.2013.02.022

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Tanenbaum ME, Gilbert LA, Qi LS, Weissman JS, Vale RD (2014) A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell 159(3):635–646. https://doi.org/10.1016/j.cell.2014.09.039

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, Stern-Ginossar N, Brandman O, Whitehead EH, Doudna JA, Lim WA, Weissman JS, Qi LS (2013) CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154(2):442–451. https://doi.org/10.1016/j.cell.2013.06.044

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Perez-Pinera P, Kocak DD, Vockley CM, Adler AF, Kabadi AM, Polstein LR, Thakore PI, Glass KA, Ousterout DG, Leong KW, Guilak F, Crawford GE, Reddy TE, Gersbach CA (2013) RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods 10:973. https://doi.org/10.1038/nmeth.2600

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead EH, Guimaraes C, Panning B, Ploegh HL, Bassik MC, Qi LS, Kampmann M, Weissman JS (2014) Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159(3):647–661. https://doi.org/10.1016/j.cell.2014.09.029

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Maeder ML, Linder SJ, Cascio VM, Fu Y, Ho QH, Joung JK (2013) CRISPR RNA-guided activation of endogenous human genes. Nat Methods 10:977. https://doi.org/10.1038/nmeth.2598

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Sanjana NE, Shalem O, Zhang F (2014) Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods 11:783. https://doi.org/10.1038/nmeth.3047

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Zischewski J, Fischer R, Bortesi L (2017) Detection of on-target and off-target mutations generated by CRISPR/Cas9 and other sequence-specific nucleases. Biotechnol Adv 35(1):95–104. https://doi.org/10.1016/j.biotechadv.2016.12.003

    Article  CAS  PubMed  Google Scholar 

  37. Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C, Hsu PD, Habib N, Gootenberg JS, Nishimasu H, Nureki O, Zhang F (2014) Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517:583. https://doi.org/10.1038/nature14136

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, Heckl D, Ebert BL, Root DE, Doench JG, Zhang F (2014) Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343(6166):84–87. https://doi.org/10.1126/science.1247005

    Article  CAS  PubMed  Google Scholar 

  39. Nihongaki Y, Yamamoto S, Kawano F, Suzuki H, Sato M (2015) CRISPR-Cas9-based photoactivatable transcription system. Chem Biol 22(2):169–174. https://doi.org/10.1016/j.chembiol.2014.12.011

    Article  CAS  PubMed  Google Scholar 

  40. Lu J, Zhao C, Zhao Y, Zhang J, Zhang Y, Chen L, Han Q, Ying Y, Peng S, Ai R, Wang Y (2018) Multimode drug inducible CRISPR/Cas9 devices for transcriptional activation and genome editing. Nucleic Acids Res 46(5):e25. https://doi.org/10.1093/nar/gkx1222

    Article  CAS  PubMed  Google Scholar 

  41. Mojica FJ, Diez-Villasenor C, Garcia-Martinez J, Almendros C (2009) Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology 155. (Pt 3:733–740. https://doi.org/10.1099/mic.0.023960-0

    Article  CAS  PubMed  Google Scholar 

  42. Doench JG, Hartenian E, Graham DB, Tothova Z, Hegde M, Smith I, Sullender M, Ebert BL, Xavier RJ, Root DE (2014) Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat Biotechnol 32(12):1262–1267. https://doi.org/10.1038/nbt.3026

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R, Virgin HW, Listgarten J, Root DE (2016) Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol 34(2):184–191. https://doi.org/10.1038/nbt.3437

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Agrotis A, Ketteler R (2015) A new age in functional genomics using CRISPR/Cas9 in arrayed library screening. Front Genet 6:300. https://doi.org/10.3389/fgene.2015.00300

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

R.J.Q. is funded by the Canadian Institutes of Health Research Doctoral Foreign Study Award. N.J.G. is a member of the Shamim and Ashraf Dahod Breast Cancer Research Laboratories and is supported by NIH grants GM117150 and CA-154531, the Karin Grunebaum Foundation, the Smith Family Awards Program, the Searle Scholars Program, and the Melanoma Research Alliance.

Author information

Authors and Affiliations

  1. Department of Pharmacology and Experimental Therapeutics, The Cancer Center, Boston University School of Medicine, Boston, MA, USA

    Ryan J. Quinton & Neil J. Ganem

  2. Division of Hematology and Oncology, Department of Medicine, Boston University School of Medicine, Boston, MA, USA

    Neil J. Ganem

Authors
  1. Ryan J. Quinton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neil J. Ganem
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neil J. Ganem .

Editor information

Editors and Affiliations

  1. Cancer Institute, University College London, London, UK

    Alexander Hergovich

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Quinton, R.J., Ganem, N.J. (2019). CRISPR-Mediated Approaches to Regulate YAP/TAZ Levels. In: Hergovich, A. (eds) The Hippo Pathway. Methods in Molecular Biology, vol 1893. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8910-2_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-8910-2_16

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-8909-6

  • Online ISBN: 978-1-4939-8910-2

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation